Adenoviral Vector for Enhanced Prostate Cancer Specific Transferrin Conjugated Drug Targeted Therapy

Prostate cancer (PCa) is one of the leading causes of death for men worldwide. Unlike some other types of cancer,there is a lack of targeted therapy for prostate cancer patients that can kill cancer cells but do much less damage to the normal tissue.In this paper, we report on an adenoviral vector enhanced prostate cancer specific transferrin conjugated drug targeted therapy. Inparticular, a functional PCa-specific gene probe is introduced to drive and up-regulate the transferrin receptor expression on the PCavia adenoviral vector. As a result, significantly enhanced accumulation of nanoscale transferrin-doxorubicin (Tf-DOX) protein drugconjugates and concomitant notably elevated PCa tumor inhibition are observed. This conceptual strategy provides the proof-of-concept for the targeted therapy of PCa that is highly desired but not yet developed

Automated summary

This paper presents a targeted therapy for prostate cancer using an adenoviral vector and transferrin-conjugated drug. By introducing a specific gene probe, the expression of transferrin receptor is up-regulated, leading to enhanced drug accumulation and inhibition of prostate cancer tumors.